Free Trial
NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Price, News & Analysis

$27.90
-0.41 (-1.45%)
(As of 07/26/2024 ET)
Today's Range
$27.51
$28.59
50-Day Range
$24.57
$28.75
52-Week Range
$16.54
$29.11
Volume
38,780 shs
Average Volume
68,232 shs
Market Capitalization
$407.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.50

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.3% Upside
$30.50 Price Target
Short Interest
Bearish
4.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.12
Upright™ Environmental Score
News Sentiment
0.50mentions of Anika Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.05) to $0.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

Medical Sector

573rd out of 936 stocks

Surgical & Medical Instruments Industry

71st out of 101 stocks

ANIK stock logo

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

ANIK Stock News Headlines

“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
“Generational Bull Run” Incoming
LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.
Anika Therapeutics Inc.: Anika Announces CFO Transition
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/27/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
300
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$30.50
High Stock Price Target
$37.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+9.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-82,670,000.00
Pretax Margin
-45.96%

Debt

Sales & Book Value

Annual Sales
$166.66 million
Cash Flow
$4.89 per share
Book Value
$14.50 per share

Miscellaneous

Free Float
13,440,000
Market Cap
$407.06 million
Optionable
Optionable
Beta
0.83

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 60)
    President, CEO & Director
    Comp: $1.34M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 50)
    Executive VP, CFO & Treasurer
    Comp: $734.14k
  • Mr. Ian W. McLeod
    VP & Chief Accounting Officer
  • Mr. Mark Namaroff (Age 61)
    Executive Director of Investor Relations & Corporate Communications
  • Mr. James Chase
    Senior Vice President of International Sales & Marketing
  • Mr. Ben Joseph
    Vice President of Commercial & Corporate Development
  • Ms. Lisa Funiciello
    Vice President of Human Resources

ANIK Stock Analysis - Frequently Asked Questions

How have ANIK shares performed this year?

Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK shares have increased by 23.1% and is now trading at $27.90.
View the best growth stocks for 2024 here
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) posted its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The biotechnology company had revenue of $40.52 million for the quarter, compared to analyst estimates of $39.23 million. Anika Therapeutics had a negative net margin of 45.39% and a positive trailing twelve-month return on equity of 0.48%.

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.42%), Allspring Global Investments Holdings LLC (0.40%), Riverwater Partners LLC (0.11%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include David Colleran, Cheryl R Blanchard, Jeffery S Thompson and Michael L Levitz.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA) and Advanced Micro Devices (AMD).

This page (NASDAQ:ANIK) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners